Biotech Values

[DewDiligence]

Thanks—my bad for misreading the PR and thinking that the ruling was on the inequitable conduct motion that was heard at the July mini-trial. That the Judge denied MYL’s motion for summary judgment on indefiniteness is a non-event insofar as the Judge previously denied an identical motion by NVS/MNTA.

The Court’s separate ruling today on the Markman hearing is somewhat of a concern to MNTA investors; however, I still expect Teva to settle the Copaxone patent case when the FDA approves NVS/MNTA’s ANDA, if the patent case has not run its course by then.